Article Text

Download PDFPDF

  1. Sodiomon Sirima1,
  2. Alfred B Tiono1,
  3. Sophie Houard2,
  4. Edith C Bougouma1,
  5. Sam A Coulibaly1,
  6. Odile Leroy2,
  7. Nirianne Palacpac3,
  8. Toshihiro Horii3,
  9. Issa N Ouedraogo1
  1. 1Centre National de Recherche et de Formation sur le Paludisme, Burkina Faso
  2. 2European Vaccine Initiative, Universitäts Klinikum Heidelberg, Germany
  3. 3Department of Molecular Protozoology, Research Institute for Microbial Diseases, Osaka University, Japan


Background The malaria blood stage vaccine candidate SE-36 is based on the serine repeat antigen of Plasmodium falciparum. Epidemiological studies have shown that antibodies against SE36 correlate with lower parasitaemia in Solomon Island residents. In a phase I b trial conducted in Uganda, the BK-SE36 vaccine, SE36 formulated with aluminium hydroxide gel, was found safe and immunogenic. Interestingly, highest levels of IgG anti-SE36 protein associated with protection against severe malaria were found in the youngest Ugandan trial participants.

Objectives To assess the safety and immunogenicity of the BK-SE36 vaccine in a randomised controlled double-blind age de-escalating phase Ib clinical trial in younger (≤5 years) malaria-exposed children living in Burkina Faso.

Methods Healthy participants (108) were included in two age cohorts, one consisting of 54 children aged 25–60 months and the other of 54 children aged 12–24 months. Trial participants received 3 intramuscular or subcutaneous injections of the BK-SE36 vaccine at Day 0, Week 4 and 26. Participants allocated to the control group received the control Synflorix vaccine via intramuscular route at Day 0 and Week 26 and saline at Week 4. The participants were followed for one year. Immune responses were evaluated by ELISA, ELISpot and parasite carriage by microscopy and PCR.

Results Preliminary data from an interim analysis (data collected one month after the last immunisation) indicated that the vaccine was safe, well-tolerated and induced an IgG anti-SE36 response in these younger populations. The trial’s latest safety, immunogenicity and preliminary efficacy results will be presented.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.